Home  /   Products  /   Dermatology  /   Azelaic acid (Skinoclear) cream 20% – [30 g tube]
Azelaic acid (Skinoclear) cream 20% - [30 g tube]

Azelaic acid (Skinoclear) cream 20% – [30 g tube]

$36.43

Acne treatment drug

SKU: 62795 Category:

Description

Skynoclear Pharmacodynamics
Causes moderate cytostatic effect (at the expense of inhibition of cell proteins synthesis), manifested in normalization of keratinization processes in the wall of sebaceous glands follicles; Has antimicrobial action (first of all, in relation to Propionibacterium acnes and Staphylococcus epidermidis) both on the surface of skin and in sebaceous glands, as well as anti-inflammatory effect (decreasing neutrophil granulocytes metabolism and production of free radical oxygen forms – important factors of inflammatory process maintenance)
Prolonged use of the drug does not form resistance of micro-organisms.
Azelaic acid dose-dependently inhibits the growth and viability of abnormal melanocytes. The therapeutic effect in hyperpigmentation (melasma) is due to inhibition of DNA synthesis and/or suppression of cellular respiration of abnormal melanocytes.

 

Indications
– Acne rashes of mild to moderate severity, including papules and pustules;
– Hyperpigmentation of the melasma type, e.g., chloasma

 

Contraindications
– Hypersensitivity to azelaic acid and other ingredients of the drug;
– Childhood under 12 years of age (acne);
– Childhood under 18 years of age (melasma-type hyperpigmentation).
Caution
In bronchial asthma.
Administration during pregnancy and lactation
It is possible to use the drug during pregnancy and lactation only after consultation with a physician.
Adequate and strictly controlled studies in external application of azelaic acid in pregnant women have not been conducted. Animal studies have shown no adverse effects of azelaic acid on pregnancy, fetal intrauterine development, delivery, or postnatal development. The potential risk to humans is unknown. In pregnancy, Skynoclear is used only if the anticipated benefit to the mother exceeds the potential risk to the fetus
It is not known whether azelaic acid penetrates into breast milk. Given the low systemic absorption of azelaic acid when used topically, Skynoclear should only be used during breastfeeding if the estimated benefit to the mother exceeds the potential risk to the baby. During breast feeding it is necessary to avoid application of the drug to the mammary gland area before breast feeding, it is necessary to avoid skin contact of children, including skin of mammary gland, after application of the drug Skynoclear.

 

Dosage and administration

 

  • Externally.
  • Before applying the cream should rinse the skin thoroughly with clean water and then dry, or use a mild cosmetic cleanser. Do not use occlusive dressings. After each application of the cream on the skin you should wash your hands. Apply a thin layer of cream to the affected areas of the skin twice a day (morning and evening), lightly rubbing into the skin (2.5 cm cream is enough for the entire surface of the face). In children 12 to 18 years of age Skynoclir is used in the treatment of acne, no dose adjustment is required. The efficacy and safety of using the drug in children under 12 years of age in the treatment of acne has not been established. The efficacy and safety of using the drug in children under 18 years of age in the treatment of melasma has not been established. It is important that the drug Skynoclir be used regularly during the entire period of treatment. The duration of treatment is individual and depends on the severity of the disease. Improvement usually occurs after 4 weeks of treatment.
  • If necessary, in the treatment of acne, it is possible to use Skynoclear for several months. In the treatment of melasma, the minimum period of treatment with Skynoclar is 3 months. During melasma treatment, sunscreens with a wide spectrum of protection against ultraviolet (UVA and UVB) radiation should always be used to prevent exacerbation of the disease and/or re-pigmentation of lightened skin areas under sun exposure. If within 1 month of treatment of acne and 3 months of treatment of melasma no improvement or exacerbation occurs, discontinue use of Skynoclyr and consult a physician. If skin irritation occurs, reduce the amount of cream at each application or reduce the frequency of use of the cream to once a day. Short-term withdrawal of the drug with subsequent resumption after disappearance of irritation symptoms at the recommended dose is possible. Use the drug only according to the method of use and in those doses that are specified in the instructions. If necessary, please consult a physician before using the drug.

Related products